Snapshot from Jul 07, 2026 at 07:00 UTC. For live data and tracking: View Live

United States & Bristol Myers Squibb

4 shared events · Importance 3 · Last updated Jul 02, 2026

Importance
3
Shared Events
4
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
52
Domestic
United States: The United States economy faces uncertainty due to new tariffs, with potential for higher inflation, dampened hiring, and increased costs for consumers and businesses.
Bristol Myers Squibb: Bristol Myers Squibb, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Sep 26, 2025 · 7 articles
42
Tech
United States: The studies discussed involve patients and practices within the United States>>> and address a significant health concern for American women.
Bristol Myers Squibb: Bristol Myers Squibb>>>'s immunotherapies Opdivo and Yervoy are mentioned as potentially faring better when patients are also taking GLP-1 drugs, suggesting a possible interaction with the immune system.
Jun 02, 2026 · 45 articles
0
Regulatory
Dec 19, 2025 · 7 articles
0
Regulatory
Bristol Myers Squibb: Bristol Myers Squibb is one of the major drugmakers that has reached pricing agreements with the Donald Trump administration to avoid the new tariffs.
Apr 02, 2026 · 23 articles
NEWSDESK
Explore this relationship live

Track how United States and Bristol Myers Squibb interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.